Section Arrow
CVM.NYSE-M
- Cel-Sci Corp
Quotes are at least 15-min delayed:2024/04/19 03:33 EDT
Last
 1.5
0 (0.00%)
Day High 
1.61 
Prev. Close
1.5 
1-M High
2.09 
Volume 
155.91K 
Bid
1.51
Ask
1.66
Day Low
1.5 
Open
1.51 
1-M Low
1.5 
Market Cap 
80.97M 
Currency USD 
P/E -- 
%Yield
10-SMA 1.66 
20-SMA 1.75 
50-SMA 2.07 
52-W High 3.23 
52-W Low 1.04 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-0.69/-0.82
Enterprise Value
92.57M
Balance Sheet
Book Value Per Share
0.23
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
BPTHBio-Path Holdings4.2+0.96+29.63%-- 
JAGXJaguar Health0.1771+0.0122+7.40%-- 
DNAGinkgo Bioworks Holdings0.9246+0.053+6.08%-- 
GERNGeron Corp3.73+0.05+1.36%-- 
OCGNOcugen1.32-0.12-8.33%-- 
Quotes are at least 15-min delayed:2024/04/19 03:33 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.